We are pleased to announce that an article featuring Rena Therapeutics was published in Nikkei Biotech.
The article highlights our development of a novel ligand capable of selectively delivering nucleic acid drugs to lymphocytes.
This recognition stems from our recent presentation at the 10th Annual Meeting of the Japanese Society of Nucleic Acid Therapeutics.
We believe that this advancement in ligand development will enable the efficient delivery of nucleic acid drugs to target cells, significantly contributing to the future development of new therapies.
For more details, please refer to the article on Nikkei Biotech.
Here is the link to the article（※To view the full text, you will need to register as a member.）